A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy
暂无分享,去创建一个
M. Jahanshahi | C. Mathias | A. Lang | N. Quinn | D. Burn | A. Schrag | I. Litvan | C. Selai | P. Low | J. Bower | S. Sheikh | A. J. Lees
[1] A. Bonnet,et al. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death , 2010, Neurobiology of Aging.
[2] Brian Spencer,et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.
[3] A. Aguzzi. Cell biology: Beyond the prion principle , 2009, Nature.
[4] B. Oken. THE PLACEBO TREATMENTS IN NEUROSCIENCES: NEW INSIGHTS FROM CLINICAL AND NEUROIMAGING STUDIES , 2009, Neurology.
[5] Martin Beibel,et al. Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.
[6] M. Diamond,et al. Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.
[7] R. Kopito,et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates , 2009, Nature Cell Biology.
[8] R. Hauser,et al. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.
[9] O. Lindvall,et al. Research in motion: the enigma of Parkinson's disease pathology spread , 2008, Nature Reviews Neuroscience.
[10] A. Berardelli,et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. , 2008, Archives of neurology.
[11] W. Oertel,et al. Pain sensitivity and descending inhibition of pain in Parkinson’s disease , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[12] B. Borroni,et al. Cognitive and behavioral assessment in the early stages of neurodegenerative extrapyramidal syndromes. , 2008, Archives of gerontology and geriatrics (Print).
[13] R. Hauser,et al. Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.
[14] Elisabet Englund,et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.
[15] E. Quagliato,et al. Pain in Parkinson's disease: analysis of 50 cases in a clinic of movement disorders. , 2008, Arquivos de neuro-psiquiatria.
[16] K. Double,et al. The comparative biology of neuromelanin and lipofuscin in the human brain , 2008, Cellular and Molecular Life Sciences.
[17] N. Quinn,et al. Survival in multiple system atrophy , 2008, Movement disorders : official journal of the Movement Disorder Society.
[18] C. Mathias,et al. Measuring health‐related quality of life in MSA: The MSA‐QoL , 2007, Movement disorders : official journal of the Movement Disorder Society.
[19] B. Cormand,et al. A homozygous tyrosine hydroxylase gene promoter mutation in a patient with dopa-responsive encephalopathy: clinical, biochemical and genetic analysis. , 2007, Molecular genetics and metabolism.
[20] V. Leuzzi,et al. Tyrosine Hydroxylase Deficiency Presenting with a Biphasic Clinical Course , 2007, Neuropediatrics.
[21] L. Golbe,et al. A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.
[22] J. Kordower,et al. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? , 2007, Neurobiology of Disease.
[23] J. Jankovic,et al. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease , 2007, Neurology.
[24] Y. Agid,et al. Dihydropteridine reductase deficiency: Levodopa’s long-term effectiveness without dyskinesia , 2006, Neurology.
[25] M. T. Pellecchia,et al. Health‐related quality of life in multiple system atrophy , 2006, Movement disorders : official journal of the Movement Disorder Society.
[26] C. Tanner,et al. Optimizing the ongoing search for new treatments for Parkinson disease , 2006, Neurology.
[27] M. T. Pellecchia,et al. Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) , 2006, Movement disorders : official journal of the Movement Disorder Society.
[28] D. Mash,et al. Natural History of Progressive Supranuclear Palsy: A Clinicopathologic Study from a Population of Brain Donors , 2005, European Neurology.
[29] A. Schrag,et al. Depressive symptoms and life satisfaction in patients with multiple system atrophy , 2005, Movement disorders : official journal of the Movement Disorder Society.
[30] A. Dagher,et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.
[31] K. Rostásy,et al. Levodopa‐responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections , 2005, Movement disorders : official journal of the Movement Disorder Society.
[32] A. Ormazabal,et al. HPLC with electrochemical and fluorescence detection procedures for the diagnosis of inborn errors of biogenic amines and pterins , 2005, Journal of Neuroscience Methods.
[33] R. Wevers,et al. Long-term course of l-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency , 2004, Neurology.
[34] D. Perl,et al. Lewy-body formation is an aggresome-related process: a hypothesis , 2004, The Lancet Neurology.
[35] S. Kish,et al. Dopa‐responsive dystonia due to mild tyrosine hydroxylase deficiency , 2004, Annals of neurology.
[36] M. Jahanshahi,et al. Health‐related quality of life in patients with progressive supranuclear palsy , 2003, Movement disorders : official journal of the Movement Disorder Society.
[37] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[38] S. Gabriel,et al. The Structure of Haplotype Blocks in the Human Genome , 2002, Science.
[39] V. Fung,et al. Tyrosine hydroxylase deficiency: Clinical manifestations of catecholamine insufficiency in infancy , 2002, Movement disorders : official journal of the Movement Disorder Society.
[40] P. Brundin,et al. Cell Survival and Clinical Outcome Following Intrastriatal Transplantation in Parkinson Disease , 2001, Journal of neuropathology and experimental neurology.
[41] G M McKhann,et al. Cell therapy for Parkinson's disease. , 2001, The New England journal of medicine.
[42] I Litvan,et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. , 2001, Archives of neurology.
[43] S. Kish,et al. Dopa-responsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations , 2001, Neurology.
[44] C. Stoll,et al. Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation , 2000, Journal of Inherited Metabolic Disease.
[45] A Schrag,et al. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population , 2000, Movement disorders : official journal of the Movement Disorder Society.
[46] R. Palmiter,et al. Dopamine-Deficient Mice Are Hypersensitive to Dopamine Receptor Agonists , 2000, The Journal of Neuroscience.
[47] R. Wevers,et al. Biochemical and molecular genetic characteristics of the severe form of tyrosine hydroxylase deficiency. , 1999, Clinical chemistry.
[48] Ornella Rimoldi,et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient , 1999, Nature Neuroscience.
[49] C. J. Mathias,et al. Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple system atrophy , 1999, Journal of Neurology.
[50] C. Marsden,et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. , 1999, Brain : a journal of neurology.
[51] F. Girotti,et al. Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy , 1999, Journal of neurology, neurosurgery, and psychiatry.
[52] R. Khurana,et al. Occurrence of depressive symptoms in Shy-Drager syndrome , 1999, Clinical Autonomic Research.
[53] F. Gabreëls,et al. Biochemical hallmarks of tyrosine hydroxylase deficiency. , 1998, Clinical chemistry.
[54] R. Wevers,et al. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population , 1998, Human Genetics.
[55] R. Hauser,et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[56] J. Hodges,et al. Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy , 1996, Journal of Neurology.
[57] R. Surtees,et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. , 1996, Human molecular genetics.
[58] N. Quinn,et al. Pain in multiple system atrophy , 1996, Journal of Neurology.
[59] L. Golbe,et al. Psychiatric symptoms in progressive supranuclear palsy. , 1995, Psychosomatics.
[60] J. Mallet,et al. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. , 1995, Human molecular genetics.
[61] P R Sanberg,et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.
[62] R. Surtees,et al. Aromatic L‐amino acid decarboxylase deficiency , 1992, Neurology.
[63] C D Marsden,et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.
[64] S. Udenfriend,et al. TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.
[65] B. Dworniczak,et al. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome , 2004, Human Genetics.
[66] N. Nishiyama,et al. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease) , 2003, Annals of neurology.
[67] M. Naumann,et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa‐nonresponsive dystonia , 2003, Annals of neurology.
[68] A. Dahlström,et al. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. , 2002, Neuroscience.
[69] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[70] W. Raub. From the National Institutes of Health. , 1990, JAMA.
[71] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.
[72] DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.
[73] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.
[74] G. Huston. The Hospital Anxiety and Depression Scale. , 1987, The Journal of rheumatology.